JP2024539989A5 - - Google Patents

Info

Publication number
JP2024539989A5
JP2024539989A5 JP2024524766A JP2024524766A JP2024539989A5 JP 2024539989 A5 JP2024539989 A5 JP 2024539989A5 JP 2024524766 A JP2024524766 A JP 2024524766A JP 2024524766 A JP2024524766 A JP 2024524766A JP 2024539989 A5 JP2024539989 A5 JP 2024539989A5
Authority
JP
Japan
Prior art keywords
antibody
linker
cancer
toxin
linker conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024524766A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539989A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/079787 external-priority patent/WO2023072934A1/en
Publication of JP2024539989A publication Critical patent/JP2024539989A/ja
Publication of JP2024539989A5 publication Critical patent/JP2024539989A5/ja
Pending legal-status Critical Current

Links

JP2024524766A 2021-10-25 2022-10-25 抗体-リンカーコンジュゲートを生成する方法 Pending JP2024539989A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21204588.4 2021-10-25
EP21204588 2021-10-25
PCT/EP2022/079787 WO2023072934A1 (en) 2021-10-25 2022-10-25 Methods for producing antibody-linker conjugates

Publications (2)

Publication Number Publication Date
JP2024539989A JP2024539989A (ja) 2024-10-31
JP2024539989A5 true JP2024539989A5 (cg-RX-API-DMAC10.html) 2025-11-14

Family

ID=78598777

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024524766A Pending JP2024539989A (ja) 2021-10-25 2022-10-25 抗体-リンカーコンジュゲートを生成する方法

Country Status (5)

Country Link
US (1) US20240398972A1 (cg-RX-API-DMAC10.html)
EP (1) EP4422695A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024539989A (cg-RX-API-DMAC10.html)
CN (1) CN118159298A (cg-RX-API-DMAC10.html)
WO (1) WO2023072934A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119375471A (zh) * 2023-07-26 2025-01-28 菲鹏生物股份有限公司 抗体和抗体缀合物及其用途
EP4721765A1 (en) 2024-10-04 2026-04-08 Commissariat à l'Energie Atomique et aux Energies Alternatives Bi-functionalized antibody conjugates against the endothelin receptor b
CN119470882B (zh) * 2025-01-08 2025-04-11 百盛(广州)生物制品有限公司 一种用于免疫组织化学染色的酶标二抗多聚物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6660510B2 (en) 2001-12-17 2003-12-09 Food Industry Research And Development Transglutaminase gene of Streptoverticillium ladakanum and the transglutaminase encoded therefrom
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2123756B1 (en) 2007-02-15 2014-06-04 Ajinomoto Co., Inc. Transglutaminase having disulfide bond introduced therein
WO2008102007A1 (en) 2007-02-22 2008-08-28 Novo Nordisk Health Care Ag Transglutaminase variants with improved specificity
EP2197443A4 (en) 2007-09-26 2014-01-01 Gemin X Pharmaceuticals Canada Inc COMPOSITIONS AND METHOD FOR LEADING NAD + MIRRORS USING A NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE HEMMER
MX2011010469A (es) 2009-04-08 2012-03-14 Deutsches Krebsforsch Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer.
EP3192529B1 (en) 2009-04-08 2020-03-25 Faulstich, Heinz, Dr. Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
AR082886A1 (es) 2010-09-03 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones farmaceuticas que los contienen
ES2402254T3 (es) 2010-09-30 2013-04-30 Heidelberg Pharma Ag Conjugados de amatoxinas con ligadores mejorados
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
EP2497499A1 (en) 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
EP2774624A1 (en) 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxin derivatives
US10195289B2 (en) 2013-07-31 2019-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
WO2015054060A1 (en) 2013-10-09 2015-04-16 Eli Lilly And Company Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors
CA2951887A1 (en) 2014-06-12 2015-12-17 Cspc Dophen Corporation Homogenous antibody drug conjugates via enzymatic methods
HUE049325T2 (hu) * 2014-08-28 2020-09-28 Pfizer Stabilitás modulátor linker antitest-hatóanyag konjugátumokhoz történõ alkalmazásra
ES2736106T3 (es) 2015-03-10 2019-12-26 Bristol Myers Squibb Co Anticuerpos que se pueden conjugar mediante la transglutaminasa y conjugados producidos a partir de ellos
EP3069734A1 (en) 2015-03-17 2016-09-21 Exiris S.r.l. Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers
WO2017025179A1 (en) 2015-08-07 2017-02-16 Merck Patent Gmbh A transglutamine tag for efficient site-specific bioconjugation
US10689458B2 (en) * 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates
AU2018337671B2 (en) 2017-09-19 2021-03-04 Paul Scherrer Institut Transglutaminase conjugation method and linker
WO2019082020A1 (en) * 2017-10-27 2019-05-02 Pfizer Inc. ANTIBODIES AND CONJUGATES CD123-SPECIFIC ANTIBODIES AND USES THEREOF

Similar Documents

Publication Publication Date Title
JP2025016545A5 (cg-RX-API-DMAC10.html)
JP2022525704A5 (cg-RX-API-DMAC10.html)
JP2023512036A5 (cg-RX-API-DMAC10.html)
JP2023546493A5 (cg-RX-API-DMAC10.html)
ES2972212T3 (es) Anticuerpos anti-interleucina-2 humana y usos de los mismos
JP7067802B2 (ja) アプタマー-薬物コンジュゲート及びその用途
JP2022530524A5 (cg-RX-API-DMAC10.html)
JP7256751B2 (ja) β-ガラクトシドが導入された自己犠牲リンカーを含む化合物
JP2025506768A5 (cg-RX-API-DMAC10.html)
JP2022547434A5 (cg-RX-API-DMAC10.html)
JP2024525624A5 (cg-RX-API-DMAC10.html)
US10618935B2 (en) Antibody-drug conjugate (ADC) and method for forming the same
CN101945892A (zh) 用于改进对表达cd138的肿瘤细胞的靶向的方法和试剂
EP4378958A3 (en) High-affinity anti-mertk antibodies and uses thereof
JP2024501894A5 (cg-RX-API-DMAC10.html)
JP2025183307A5 (cg-RX-API-DMAC10.html)
CN109963620A (zh) 细胞靶向缀合物
JP2023542910A5 (cg-RX-API-DMAC10.html)
CN111093701A (zh) 含有抗globo h抗体的抗体药物偶联物及其用途
JP2025501978A5 (cg-RX-API-DMAC10.html)
JP2024542095A5 (cg-RX-API-DMAC10.html)
KR20250137203A (ko) 항체 약물 접합체
NZ306768A (en) Anti-AIDS immunotoxins with a toxin conjugated to a monoclonal antibody
JPH0641423B2 (ja) 細胞毒性薬剤組成物及び細胞毒性薬剤キット
EP1230270A1 (en) Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents